Sexual health information · GREENWOOD, IN
PT-141 (Bremelanotide): Sexual Health Information
Changes in sexual desire can be difficult to talk about, but you deserve a thoughtful, judgment-free conversation. At Elevate Health in Greenwood, Indiana, we consider your concerns, health history and preferences before discussing whether a treatment may be appropriate.
What is PT-141?
PT-141 is another name for bremelanotide, a peptide that acts on melanocortin receptors. Vyleesi is an FDA-approved bremelanotide injection for a specific form of low sexual desire in premenopausal women. The approval applies to Vyleesi, not to every product containing bremelanotide.
In clinical trials of eligible women, Vyleesi improved average measures of desire and related distress compared with placebo. Individual responses vary, and treatment does not guarantee improvement. It is not indicated to enhance sexual performance.
Who is Vyleesi approved for?
Vyleesi is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD. This means a previously absent problem with low desire that causes marked distress or relationship difficulty and occurs regardless of the situation, partner or type of stimulation. The low desire must not be due to a medical or psychiatric condition, relationship problems, or the effects of a medication or other drug.
Vyleesi is not indicated for HSDD in men or postmenopausal women. A clinician may sometimes prescribe an FDA-approved medicine for an unapproved, or off-label, use when medically appropriate. Off-label does not automatically mean illegal, but the FDA has not established safety and effectiveness for that use. Discuss the evidence, uncertainties, alternatives and your goals before deciding.
Blood pressure and other safety considerations
Vyleesi must not be used by people with uncontrolled high blood pressure or known cardiovascular disease. Each dose can temporarily raise blood pressure and lower heart rate. It is not recommended for people at high risk of cardiovascular disease. A clinician should assess cardiovascular risk and make sure blood pressure is well controlled before treatment and periodically during it.
Nausea is common. In Vyleesi trials, about 40% of treated participants reported nausea compared with about 1% of those receiving placebo. Flushing, injection-site reactions, headache and vomiting can also occur. Contact your clinician for severe or persistent nausea. Areas of skin or gums may darken and may not fully return to their previous color; report new pigmentation changes.
Medicines, pregnancy and breastfeeding
Vyleesi may slow stomach emptying and affect how some medicines taken by mouth are absorbed. It should be avoided with oral naltrexone products used to treat alcohol or opioid addiction because their effectiveness can be reduced. Give your clinician a complete list of medicines and supplements so other interactions can be reviewed.
Tell your clinician if you are pregnant, planning pregnancy or breastfeeding. The Vyleesi label advises effective contraception for patients who could become pregnant. Stop Vyleesi and contact your clinician if pregnancy is suspected. There is no information on whether bremelanotide passes into human milk.
What using Vyleesi involves
Vyleesi is a prescription, as-needed injection supplied in a prefilled autoinjector. Its label directs use at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours. More than eight doses per month is not recommended. Your prescriber or pharmacist should explain the product-specific instructions before use.
The label recommends stopping Vyleesi if symptoms have not improved after eight weeks. Follow-up also provides a chance to discuss side effects and whether the treatment remains appropriate. These instructions are for Vyleesi and should not be assumed to apply to a different preparation.
Product choice and informed decisions
Compounding can meet an individual need when an FDA-approved medicine cannot. Compounded drugs are not FDA approved and are not reviewed by the FDA for safety, effectiveness or quality before marketing. They are not interchangeable with Vyleesi simply because they contain bremelanotide. Availability of a particular compounded substance or route is subject to applicable law and practice evaluation.
Elevate Health works with reputable licensed compounding pharmacies that provide certificates of analysis and use third-party testing. Our pharmacy partners follow applicable federal and state requirements, including sterile compounding standards where relevant. Documentation can vary by product. A care discussion should cover the exact product, its regulatory status, potential benefits and risks, alternatives, costs and follow-up before you decide.
Frequently asked questions
Is PT-141 FDA approved for men or postmenopausal women?
FDA-approved Vyleesi is indicated for acquired, generalized HSDD in premenopausal women, not for HSDD in men or postmenopausal women or for enhancing sexual performance. A clinician may consider off-label use of an approved medicine in some circumstances, but FDA has not established its safety and effectiveness for that unapproved use.
Does low desire always mean I need medication?
No. Desire can be affected by health conditions, medications, relationship concerns and many other factors. An assessment can help identify possible contributors and discuss appropriate alternatives as well as medication when relevant.
Is compounded bremelanotide the same as a research-only product?
No. A compliant licensed compounding pharmacy prepares medicines under applicable pharmacy and compounding requirements, often for an individual patient's needs. Compounded products are not FDA approved. Products labeled for research use only are not intended for human use and may have uncertain contents, strength or sterility. Elevate Health does not use grey-market peptides labeled for research use only or not for human consumption in patient care.
What should I do if I am taking oral naltrexone or might be pregnant?
Tell your clinician before using Vyleesi. Its label says to avoid Vyleesi with oral naltrexone used for alcohol or opioid addiction. Use effective contraception if you could become pregnant, and stop Vyleesi and contact your clinician if pregnancy is suspected.
Will Elevate Health prescribe or supply PT-141?
A discussion does not guarantee a prescription or supply. Appropriate treatment and the availability of a particular product or route depend on your evaluation, practice policies and applicable law. Ask about the exact product and any expected costs or coverage.
Care starts with a conversation
Have questions about your options? Our team can help you take the next step with an individualized consultation.
Visiting Elevate Health in Greenwood
Our office is in Greenwood, Indiana. We welcome patients traveling from Trafalgar, Greensburg and Indianapolis, and other Indiana communities. View our contact information and communities served.
